il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells (Biological)
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2019 (NCT04003649)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma of Lung · Phase 1
- Adrenocortical Carcinoma · Phase 1
- Biomarkers · Phase 1
- Breast Neoplasms · Phase 1
- Glioblastoma · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Neuroendocrine Tumors · Phase 1
- Pancreatic Neoplasms · Phase 1
- Paraganglioma · Phase 1
- Pheochromocytoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Thyroid Neoplasms · Phase 1
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04119024 | Phase 1 | Oct 1, 2019 | City of Hope National Medical Center, University of California, Los Angeles |
| NCT04003649 | Phase 1 | Aug 1, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 2 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1